FILE:COV/COV-8K-20080418161147.txt.gz
EVENTS:	Completion of Acquisition or Disposition of Assets	Regulation FD Disclosure	Financial Statements and Exhibits
TEXT:
ITEM: Completion of Acquisition or Disposition of Assets
ITEM: Regulation FD Disclosure
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
On April 18, 2008, Covidien Ltd. (the "Company") completed the previously announced sale of its Retail Products business to First Quality Enterprises, Inc., for $330 million in cash. As part of the sale transaction, First Quality will assume ownership of the Company's private-label infant care, incontinence and feminine hygiene manufacturing business, including all of the related U.S. plants and distribution centers. The sale excludes the Company's manufacturing plant in Tijuana, Mexico, which the Company will retain. As part of the sale transaction, the Company has agreed to use this plant to produce and supply products solely to First Quality for a period of up to five months.
Financial statements accounting for the Retail Products business as a discontinued operation were included in the Company's Interim Report on Form 10-Q for the quarter ended December 28, 2007 and as an exhibit to the Company's Current Report on Form 8-K dated April 15, 2008, both of which were filed with the Securities and Exchange Commission.
 
On April 18, 2008, the Company issued a press release announcing the completion of the sale of its Retail Products business to First Quality Enterprises, Inc. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: April 18, 2008
 
 

Exhibit 99.1
COVIDIEN COMPLETES SALE OF RETAIL PRODUCTS BUSINESS
Hamilton, Bermuda  April 18, 2008  Covidien Ltd. (NYSE: COV, BSX: COV) today announced that it had completed the previously announced sale of its Retail Products business to an affiliate of First Quality Enterprises, Inc. for $330 million in cash.
The sale of Retail Products is part of Covidien's strategy to focus its portfolio and reallocate resources to its core healthcare business. This portfolio strategy also includes the previously-announced definitive agreement to sell Covidien's European Incontinence business, as well as the plan to divest its Specialty Chemicals business.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.
Contacts:
Eric Kraus
Senior Vice President
Corporate Communications
508-261-8305
eric.kraus@covidien.com
Coleman Lannum, CFA
Vice President
Investor Relations
508-452-4343
cole.lannum@covidien.com
Bruce Farmer
Vice President
Public Relations
508-452-4372
bruce.farmer@covidien.com
Wayde McMillan
Director
Investor Relations
508-452-4387
wayde.mcmillan@covidien.com


